Evidence map›Paper›PMID 25031584›Full record

ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2014

Effect of ketotifen premedication on adverse reactions during peanut oral immunotherapy.

Amanda Jagdis, Noam Berlin, Carly Barron, Mohana Giruparajah, Nathan Leader, Sean Maclachlan, Gordon L Sussman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 26 citations in OpenAlex.

  1. Practical issues of oral immunotherapy for egg or milk allergy.Clinical and experimental pediatrics · 2024
    Article
  2. Article
  3. Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Amanda JagdisDivision of Clinical Immunology and Allergy, Department of Medicine, University of Toronto, 202 St Clair Ave W, Toronto, ON M4V 1R2, Canada.
Noam BerlinFaculty of Medicine, University of Toronto, Toronto, ON, Canada.
Carly BarronGordon Sussman Clinical Research Inc., Toronto, ON, Canada.
Mohana GiruparajahGordon Sussman Clinical Research Inc., Toronto, ON, Canada.
Nathan LeaderMelbourne Medical School, University of Melbourne, Melbourne, Australia.
Sean MaclachlanFaculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Gordon L SussmanDivision of Clinical Immunology and Allergy, Department of Medicine, University of Toronto, 202 St Clair Ave W, Toronto, ON M4V 1R2, Canada.
University of Toronto · CAUniversity of Melbourne · AUUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOral immunotherapy (OIT) has shown promise in inducing desensitization for food allergy. However, there are safety concerns regarding the frequency and severity of adverse events during food OIT.

objectiveTo evaluate the effect of Ketotifen premedication on adverse reactions during peanut OIT.

methodsA randomized single blind placebo controlled pilot study was performed. Peanut OIT was performed using a previously published protocol. Ketotifen was up-titrated to 2 mg twice daily over two weeks (week -2 to 0), followed by a peanut OIT initial escalation day (day 1). Ketotifen was administered from week 0-4 of peanut OIT; reactions to peanut OIT doses were recorded by clinic staff and subject diary.

resultsSix subjects (median age 10 years, peanut IgE >100kUA/L) were enrolled, 4 randomized to Ketotifen, 2 to placebo. The most common side effect of Ketotifen was fatigue (9% during up-titration). The rate of reaction per peanut OIT dose was lower for subjects on ketotifen (K) compared to placebo (P) during initial escalation on day 1 (K: 22% (8/36) vs. P: 67% (12/18)); week 0-4 build-up doses (K: 75% (3/4) vs. P: 100% (2/2)); and week 0-4 home doses (K: 50% (54/108) vs. P: 82% (27/33)). The rate of gastrointestinal symptoms per peanut OIT dose was also lower for subjects on ketotifen during initial escalation on day 1 (K: 17% (6/36) vs. P: 61% (11/18)); week 0-4 build-up doses (K: 75% (3/4) vs P: 100% (2/2)); and week 0-4 home doses (K: 46% (50/108) vs. P: 82% (27/33)).

conclusionsKetotifen premedication is well tolerated and reduces the rate of gastrointestinal symptoms during peanut OIT. These findings require confirmation in a larger study of Ketotifen premedication used throughout peanut OIT.

trial registrationCLINICAL TRIALS NUMBER: NCT0162515.

Indexed as

Adverse reactionsAntihistamine premedicationDesensitizationKetotifenOral immunotherapyPeanut allergy

Identifiers

PMID25031584
PMCPMC4099498
OpenAlexW2163993539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.